Reimbursement challenges with cancer immunotherapeutics

Related Experiment Video

Updated: May 19, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Alex Kudrin1

  • 1koudrine@hotmail.com

Human Vaccines & Immunotherapeutics
|August 17, 2012
PubMed

Insights

Cancer vaccine developers must analyze cost-effectiveness and engage stakeholders early. Early patient-reported outcomes data collection is crucial for demonstrating value and facilitating market access for new immunotherapies.

Area of Science:

  • Oncology
  • Health Economics
  • Immunotherapy

Background:

  • Cancer vaccine development requires expertise in immunology, clinical trials, and economic analysis.
  • EU health technology bodies evaluate new therapies based on clinical and economic value, considering budget uncertainties.
  • Market access for novel oncology treatments often involves risk-sharing agreements with payers.

Purpose of the Study:

  • To review the methodologies used by EU health technology bodies for appraising new cancer therapies.
  • To highlight the importance of economic and clinical value assessment in market access.
  • To provide insights into risk-sharing agreements for oncology treatments.

Main Methods:

  • Review of methodologies employed by European health technology assessment (HTA) bodies.
  • Analysis of economic and clinical value appraisal frameworks.
  • Examination of risk-sharing agreements in the EU market for oncology treatments.

Main Results:

  • New oncology treatments increasingly access the EU market via risk-sharing agreements.
  • Early collection of patient-reported outcomes (PROs) can enhance the projected clinical and economic value of immunotherapies.
  • Proactive engagement with stakeholders, including patient organizations, physicians, and payers, is vital for market access.

Conclusions:

  • Cancer vaccine developers need to integrate economic evaluation and stakeholder engagement into their strategies.
  • Demonstrating additional clinical and economic value through early PRO collection is essential.
  • Facilitating market access requires early and continuous interaction with all relevant parties.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...